Shares of Concord Biotech surged nearly 5% to ₹1,750 in early trade on May 30 after the company reported a robust set of numbers for the fourth quarter ended March 31, 2025.
The company’s consolidated revenue rose 34.8% year-on-year to ₹430 crore in Q4 FY25, compared to ₹319 crore in the same period last year. Strong operational efficiency pushed EBITDA up by 41.8% to ₹190 crore, while EBITDA margin expanded to 44.3% from 42.1% YoY.
Net profit for the quarter jumped 47.8% to ₹140 crore, compared to ₹95 crore a year earlier.
Concord Biotech also declared a dividend of ₹10.7 per share, reflecting its strong financial position and commitment to shareholder returns.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions.
